Clinical Trial Update: An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress [Phase 2]

View source ↗

Summary

Phase 2 trial results for JNJ-42165279 in adults with major depressive disorder with anxious distress, detailing efficacy, safety and tolerability with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorder
• Major Depressive Disorder

Drugs mentioned

• JNJ-42165279

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Depressive Disorder, Anxiety | Phase 2 | Status: COMPLETED | Results posted: 2022-04-07